NMOSD

Nerve Tissue Scarring May Explain MS Progression

Nerve tissue scars associated with multiple sclerosis (MS) show marked differences from those of similar neurodegenerative disorders, according to a recent study. MS-associated inflammation causes brain and spinal cord lesions (nerve tissue scarring) that often are bigger and last longer than those of two other demyelinating diseases: myelin oligodendrocyte…

Pregnancy Worsens Symptoms in MS Patients, Study Finds

Pregnancy, including successful delivery or miscarriage, worsensĀ symptoms of multiple sclerosis (MS), as well as onset of the disease, a retrospective study shows. Researchers found the same effect of pregnancy on neuromyelitis optica spectrum disorders (NMOSD), an inflammatory disorder of the central nervous system characterized by demyelination and damage of…

TG Therapeutics’ Potential Neuromyelitis Optica Treatment Named Orphan Drug by FDA

TheĀ U.S. Food and Drug AdministrationĀ (FDA) has designated TG-1101Ā (ublituximab), aĀ glycoengineered anti-CD20 monoclonal antibody byĀ TG Therapeutics, anĀ orphan drugĀ to advance its development. The drug is a potentialĀ treatment for neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD), two relapsing-remitting autoimmune diseases with similarities to multiple sclerosis. Currently, there are…

People with Relapsing NMOD Invited to Enter Phase 3 Study

The National Multiple Sclerosis Society recently announced that a research team is recruiting 132 patients with a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) for a Phase 3 clinical study comparing an experimental medicine with an inactive placebo. NMOSD is a rare disorder caused by immune system cells attacking…